Compare ENTX & NOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | NOMA |
|---|---|---|
| Founded | 2010 | 2023 |
| Country | Israel | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 65.4M |
| IPO Year | 2015 | N/A |
| Metric | ENTX | NOMA |
|---|---|---|
| Price | $1.18 | $3.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 85.4K | 8.3K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $2.55 |
| 52 Week High | $3.22 | $10.00 |
| Indicator | ENTX | NOMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 48.33 |
| Support Level | $1.07 | $3.35 |
| Resistance Level | $1.37 | $4.69 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 2.38 | 70.37 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.